These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 14745094)

  • 1. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Montgomery EB
    Neurology; 2004 Jan; 62(2):343; author reply 343-5. PubMed ID: 14745094
    [No Abstract]   [Full Text] [Related]  

  • 2. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Pan T; Le W; Jankovic J
    Neurology; 2004 Jan; 62(2):343; author reply 343-4. PubMed ID: 14750218
    [No Abstract]   [Full Text] [Related]  

  • 3. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 4. The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
    MacMahon DG
    Age Ageing; 2003 May; 32(3):244-5. PubMed ID: 12720606
    [No Abstract]   [Full Text] [Related]  

  • 5. Current advances in Parkinson's disease.
    Ball J
    Trends Neurosci; 2001 Jul; 24(7):367-9. PubMed ID: 11467283
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine agonists in early therapy for Parkinson disease: promise and problems.
    Tanner CM
    JAMA; 2000 Oct; 284(15):1971-3. PubMed ID: 11035895
    [No Abstract]   [Full Text] [Related]  

  • 7. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 8. Do dopamine agonists or levodopa modify Parkinson's disease progression?
    Marek K; Jennings D; Seibyl J
    Eur J Neurol; 2002 Nov; 9 Suppl 3():15-22. PubMed ID: 12464117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved].
    MMW Fortschr Med; 2002 May; Suppl 2():88. PubMed ID: 12070869
    [No Abstract]   [Full Text] [Related]  

  • 12. Several classes of new drugs emerging for Parkinson disease.
    Phillips P
    JAMA; 1999 Sep; 282(10):929-31. PubMed ID: 10485664
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group.
    Clin Neuropharmacol; 2000; 23(1):34-44. PubMed ID: 10682229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
    Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.
    Marek K; Jennings D; Seibyl J
    Neurology; 2003 Sep; 61(6 Suppl 3):S43-8. PubMed ID: 14504379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.